Eli Lilly is using the GLP-1 windfall to good effect Mounjaro and Zepbound currently make up nearly two-thirds of Eli Lilly's sales
Authorized generic competition during the 180-day exclusivity period reduces the first-filer generic manufacturers revenues by an average of 52 percent compared with situations where no authorized generic competes during the exclusivity period. Federal Trade Commission, Authorized Generic Drugs: Short-Term Effects and Long-Term Impact (2011), p
See my options Editorial update What to know before deciding Updated Jul 21, 2026 Zepbound Before and After is easiest to understand when the entity, mechanism, evidence limits, safety questions, access, and nearby alternatives are explained in that order
Specifically, tirzepatide prescriptions increased from 0.7% in 2022 to 2.8% in 2025, whereas semaglutide prescriptions decreased from 4.2% in 2022 to 2.1% in 2025
8 (Suppl 3): S233S244
Sustained Benefits Make no mistake about it